Table 1.
Cancer risk after renal transplantation in Australia and the United States
| Cancers | Cumulative Incidence (/100,000)Australia | Cumulative Incidencea (/100,000)United States | SIRb |
||
|---|---|---|---|---|---|
| Australia | United States |
||||
| Male | Female | ||||
| Kaposi sarcoma | 213 | 140 | 21.30 | 17.4 | 62.0 |
| Kidney/ureter | 139 | 1010 | 10.39 | 14.1 | 14.6 |
| Lymphoma | 189 | 80 | 7.40 | 6.9 | 29.1 |
| Bladder | 90 | 126 | 5.03 | 1.6 | 3.6 |
| Esophagus | 40 | 70 | 4.00 | 2.4 | 2.8 |
| Cervix | 35 | 180 | 3.85 | – | 5.7 |
| Liver | 20 | 220 | 2.99 | 4.2 | 4.5 |
| Melanoma | 129 | 320 | 2.14 | 6.9 | 5.2 |
| Lung/bronchus/trachea | 85 | 690 | 1.89 | 2.3 | 3.6 |
| Colorectal | 169 | 510 | 2.51 | 1.6 | 2.8 |
| Breast | 100 | 1050 | 0.98 (female) | 4.0 | 1.1 |
| Prostate | 40 | 1740 | 0.95 | 1.6 | – |
Cumulative incidence is calculated at 3 yr after transplantation.
Standardized incidence ratio (SIR) (ANZDATA) is calculated as the "observed/expected" number of cases for each cancer type. The "expected number of cases" is calculated overall and for each type by comparing the observed number of cases seen in an age-matched New South Wales population using the mean population for same years. SIR (US Renal Data System) is calculated as the "observed/expected" number of cases for each cancer type 3 yr after transplantation. The "expected number of cases" is calculated overall and for each type by comparing the observed number of cases seen in the age matched SEER population in year 2000 (1).